Open access
Open access
Powered by Google Translator Translator

Phase 1/2 randomized trial: safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2

21 Jul, 2020 | 09:33h | UTC

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial – The Lancet

Commentaries: New study reveals Oxford coronavirus vaccine produces strong immune response – University of Oxford AND Oxford’s Covid-19 vaccine appears safe and induces immune response, early results suggest, but more research is needed – CNN AND Early Oxford-AstraZeneca Coronavirus Vaccine Data ‘Encouraging,’ Scientists Say – NPR

 

Related Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.